Glioblastoma Clinical Trial Monitor — GBM & Brain Cancer Programs

The glioblastoma clinical trial landscape in 2026

Glioblastoma (GBM) remains one of the most challenging cancers — median overall survival of 14–16 months from diagnosis has barely moved in 20 years despite enormous research investment. This treatment gap, combined with the high emotional urgency of brain cancer, drives patients, families, and clinicians to actively seek clinical trials. It also means the GBM trial landscape remains active with new mechanisms constantly entering Phase 1.

For neuro-oncology pharma teams, the GBM space is characterized by high trial activity, difficult CNS delivery challenges, and a pattern of Phase 2 results that don't replicate in Phase 3. Monitoring new trial registrations helps CI teams catch emerging mechanisms before they reach pivotal studies.

Active Phase 3 glioblastoma trials (2026)

Key Phase 3 and pivotal GBM studies currently recruiting or in startup:

NCT ID	Trial / Agent	Sponsor	Status
NCT06556563	Optune (TTFields) + temozolomide + pembrolizumab in newly diagnosed GBM (EF-41/KEYNOTE D58)	NovoCure	Recruiting
NCT07100730	TLX101-Tx (targeted radiotherapy) + standard of care in newly diagnosed GBM	Telix Pharmaceuticals	Recruiting
NCT06388733	Niraparib vs temozolomide in newly diagnosed MGMT-unmethylated GBM	Ivy Brain Tumor Center	Recruiting
NCT07195591	GammaTile (brachytherapy) immediately at resection vs standard RT in GBM	GT Medical Technologies	Recruiting
NCT05904119	Lomustine with/without reirradiation at first GBM progression (EORTC)	EORTC	Recruiting
NCT07349693	Cerebraca Wafer + temozolomide vs temozolomide alone in recurrent GBM	Everfront Biotech	Not Yet Recruiting
NCT07452458	Temporally-modulated pulsed RT vs standard RT in GBM (NRG)	NRG Oncology	Not Yet Recruiting
NCT05095376	Adding lomustine to standard temozolomide + RT in newly diagnosed GBM (NRG)	NRG Oncology	Recruiting

Key mechanisms generating new GBM trials

EGFR and EGFRvIII targeting

EGFR amplification and EGFRvIII mutation are among the most common genetic alterations in GBM, making them attractive targets. Multiple generations of EGFR-targeting approaches are in trials:

• EGFRvIII-targeted CAR-T: multiple programs testing locoregional and systemic delivery
• Bispecific antibodies targeting EGFRvIII × CD3 for T cell engagement
• EGFR-targeted ADCs with improved CNS penetration
• Third-generation EGFR TKIs with better blood-brain barrier penetration
• Vaccine approaches: EGFRvIII peptide vaccines and mRNA vaccines

IDH1/IDH2 mutations in lower-grade glioma

IDH-mutant gliomas (WHO Grade 2–3) are biologically distinct from IDH-wildtype GBM. Vorasidenib, approved for IDH-mutant Grade 2 glioma, has opened a new treatment era:

• Vorasidenib combinations with temozolomide or radiation
• Next-generation IDH inhibitors with improved CNS penetration
• IDH-mutant specific immunotherapy approaches (IDH mutation as neoantigen)
• Treatment-naive IDH-mutant Grade 3 glioma: new frontline approaches

Immunotherapy: overcoming the immunosuppressive GBM microenvironment

GBM is notoriously immunosuppressed — multiple Phase 3 checkpoint inhibitor trials have failed. The new wave of immunotherapy trials takes different approaches:

• Locoregional delivery of immunotherapy agents (intratumoral or intracavitary injection)
• CAR-T with armored constructs overcoming TGF-β and IL-10 suppression
• Oncolytic viruses: DNX-2401, G207, and next-generation engineered viruses
• CAR-T + checkpoint inhibitor combinations delivered locally
• B7-H3 targeted therapies (highly expressed in GBM)

Tumor treating fields (TTFields) combinations

Optune (TTFields) is standard of care in newly diagnosed GBM per NCCN guidelines. Active trial areas include:

• TTFields + chemotherapy backbones beyond temozolomide
• TTFields + immunotherapy (pembrolizumab, ipilimumab/nivolumab)
• TTFields in recurrent GBM with novel systemic combinations
• Wearable array optimization: increased frequency, new placement protocols

Anti-VEGF approaches and anti-angiogenesis

Bevacizumab improves progression-free survival in GBM without OS benefit. New approaches try to overcome resistance:

• Anti-VEGF + immunotherapy: hypothesis that VEGF blockade normalizes tumor vasculature to improve T cell infiltration
• Dual VEGF/ANG2 targeting (vanucizumab follow-ons)
• Small molecule VEGFR inhibitors with CNS penetration

MGMT methylation: the predictive biomarker driving stratification

MGMT promoter methylation predicts benefit from temozolomide and is now a standard stratification factor. Trials increasingly design separate arms or specific programs for MGMT-methylated vs. unmethylated GBM.

Who monitors glioblastoma clinical trials?

• Neuro-oncology pharma and biotech teams tracking competitor programs in a notoriously difficult oncology indication
• Clinical development leaders designing new Phase 1/2 GBM trials who need a comprehensive view of current mechanism and delivery approach diversity
• Academic neuro-oncology centers (MD Anderson, UCSF, Dana-Farber) reviewing what trials are active for patient referral and site participation decisions
• Healthcare investors following GBM biotech — a space where Phase 2 data frequently misleads, making competitive landscape awareness critical
• Patient advocacy organizations (National Brain Tumor Society) tracking the pipeline for patient communication

Related oncology and neurology clinical trial monitors

• ALS clinical trials — related CNS drug delivery challenges and neurological disease research
• Melanoma clinical trials — overlapping immunotherapy approaches and brain metastasis programs
• NSCLC clinical trials — shared brain metastasis treatment programs and checkpoint inhibitor CNS activity data